Status: Recruiting
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
Participants needed: 75
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Epigenetix, Inc.Updated: Jan 14, 2025Locations: 6
Eligibility criteria
Relapse or refractory castration-resistant prostate cancer (CRPC) following at l... [+6]
New and progressive central nervous system (CNS) metastasis; patients with treat... [+5]